Nuveen Asset Management LLC Grows Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Nuveen Asset Management LLC increased its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 37.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,296,366 shares of the medical instruments supplier’s stock after purchasing an additional 353,070 shares during the quarter. Nuveen Asset Management LLC owned 3.20% of AngioDynamics worth $11,875,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of ANGO. SBI Securities Co. Ltd. acquired a new position in shares of AngioDynamics during the 4th quarter valued at $28,000. R Squared Ltd purchased a new position in AngioDynamics in the fourth quarter valued at about $49,000. US Bancorp DE lifted its stake in shares of AngioDynamics by 1,938.0% during the fourth quarter. US Bancorp DE now owns 6,705 shares of the medical instruments supplier’s stock worth $61,000 after purchasing an additional 6,376 shares in the last quarter. Quinn Opportunity Partners LLC acquired a new position in shares of AngioDynamics during the fourth quarter worth about $92,000. Finally, Graham Capital Management L.P. purchased a new stake in shares of AngioDynamics in the fourth quarter worth about $106,000. Hedge funds and other institutional investors own 89.43% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target (up previously from $15.00) on shares of AngioDynamics in a research note on Monday, April 7th.

AngioDynamics Trading Up 0.4%

ANGO stock opened at $9.45 on Tuesday. The firm has a 50 day simple moving average of $9.47 and a 200-day simple moving average of $9.53. The company has a market capitalization of $383.74 million, a P/E ratio of -1.68 and a beta of 0.58. AngioDynamics, Inc. has a twelve month low of $5.47 and a twelve month high of $13.50.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Wednesday, April 2nd. The medical instruments supplier reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.16. The company had revenue of $72.00 million during the quarter, compared to analyst estimates of $70.30 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The firm’s quarterly revenue was down 4.3% on a year-over-year basis. On average, research analysts predict that AngioDynamics, Inc. will post -0.37 EPS for the current year.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.